Delaware court dismisses Accord claims in Seroquel antitrust litigation
Plaintiffs have failed to allege that AstraZeneca’s purported pay-for-delay agreement with Accord Healthcare harmed competition in the market for psychiatric medication Seroquel XR, a federal court has ruled.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10